







Globally	 affecting	more	 than	 one	million	 new	 persons	 each	 year,	 and	 killing	more	 than	 700,000,	
colorectal	cancer	is	the	second	leading	cause	of	cancer-related	deaths	in	women	and	the	third	in	men.	
Nevertheless,	 diagnosis	 is	 still	 largely	 based	on	 invasive	 tissue	 sampling,	while	 gaps	 remain	 in	 the	
understanding	 of	 its	 pathogenesis,	 with	 complex	 combinations	 between	 lifestyle,	 genetics,	




GC-MS	 Orbitrap	 system	 to	 detect	 and	 identify	 metabolites	 related	 to	 colorectal	 cancer	 in	 an	
untargeted	 manner	 was	 assessed.	 The	 workflow	 uses	 the	 advantages	 of	 high	 peak	 capacity	 and	
chromatographic	 resolution	 of	 gas	 chromatography	 with	 the	 high	 resolution	 and	 sub-ppm	 mass	
accuracy	 of	 the	 Orbitrap	mass	 spectrometer.	 The	 samples	 analyzed	 belonged	 to	 two	 populations	
linked	to	colorectal	adenocarcinoma	(active	and	remission,	12	samples	each)	along	with	two	controls	
cohorts	of	the	same	size	specifically	matched	for	possible	biases	(gender,	age,	BMI,	smoking	status	
etc.),	 and	pooled	QC	samples.	Analytical	 raw	data	 files	were	automatically	processed	 through	 two	
software	platforms	specifically	designed	for	the	Orbitrap	technology	(TraceFinder™	and	Compound	
Discoverer™).	Compound	identification	was	made	using	existing	commercial	libraries	as	well	as	an	in-
house	developed	high	resolution	Orbitrap	metabolomics	library.	
